Stocklytics Platform
LIXT
Lixte Biotechnology Holdings
LIXTW3
$0.06arrow_drop_down16.00%-$0.01
Penny Stock
LIXT
LIXTW3

$0.06

arrow_drop_down16.00%

Performance History

Chart placeholder
Key Stats
Open$0.06
Prev. Close$0.07
EPS-
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap-
PE Ratio-
LOWHIGH
Day Range0.06
0.06
52 Week Range0.03
0.11
Ratios
Revenue-
EBITDA Margin %-
EPS-

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol CAT
Caterpillar
CAT78
Price$350.48
Perf. (24h)
arrow_drop_up1.79%$6.18
Market Cap$171.40B
HTFC
Horizon Technology Finance Corporation 6.25% Notes due 2027
HTFC26
Price$23.75
Perf. (24h)
arrow_drop_down0.34%-$0.08
Market Cap$36.94B
OXLC
Oxford Lane Capital Corp. - 5.00% Notes due 2027
OXLCZ35
Price$23.39
Perf. (24h)
arrow_drop_up0.30%$0.07
Market Cap$36.68B
RWAY
Runway Growth Finance Corp. - 7.50% Notes due 2027
RWAYL35
Price$25.02
Perf. (24h)
arrow_drop_up0.08%$0.02
Market Cap$12.73B

About Lixte Biotechnology Holdings (LIXTW)

Lixte Biotechnology Holdings, Inc. (LIXTW) is a biotechnology company that specializes in the development of personalized medicine for the treatment of various cancers. The company's focus is on the discovery and development of small molecule inhibitors that target signaling pathways involved in the growth and survival of cancer cells. Lixte Biotechnology Holdings aims to provide innovative therapies that offer improved outcomes for patients with limited treatment options.
LIXTW stock has a price history that reflects the company's progress and potential. Investors can review the stock's performance over time to assess its stability and growth potential. Lixte Biotechnology Holdings stock quote can provide the current market price and trading information for interested investors. Updated stock news and analysis can also be found, providing valuable insights into the company's recent activities and performance.
Sector
Industry
CEO
Headquarters
Employees
0
Exchange
NASDAQ
add Lixte Biotechnology Holdings to watchlist

Keep an eye on Lixte Biotechnology Holdings

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Lixte Biotechnology Holdings's (LIXTW) price per share?
The current price per share for Lixte Biotechnology Holdings (LIXTW) is $0.06. The stock has seen a price change of -$0.01 recently, indicating a -16% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Lixte Biotechnology Holdings (LIXTW)?
For Lixte Biotechnology Holdings (LIXTW), the 52-week high is $0.11, which is 74.6% from the current price. The 52-week low is $0.03, the current price is 110% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Lixte Biotechnology Holdings (LIXTW) a growth stock?
Lixte Biotechnology Holdings (LIXTW) has shown an average price growth of 0.41% over the past three years. It has received a score of 0 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Lixte Biotechnology Holdings as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Lixte Biotechnology Holdings (LIXTW) stock price performance year to date (YTD)?
As of the latest data, Lixte Biotechnology Holdings (LIXTW) has a year-to-date price change of 34.04%. Over the past month, the stock has experienced a price change of 56.72%. Over the last three months, the change has been 26%. Over the past six months, the figure is -8.7%.
help
Is Lixte Biotechnology Holdings (LIXTW) a profitable company?
Lixte Biotechnology Holdings (LIXTW) has a net income of -$5.09M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$5.09M. Furthermore, the EBITDA is $0.
help
What is the market capitalization of Lixte Biotechnology Holdings (LIXTW)?
Lixte Biotechnology Holdings (LIXTW) has a market capitalization of . The average daily trading volume is 6.44K, indicating the stock's liquidity and investor engagement.

News

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
PRESS RELEASES
6/14/2024

LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
PRESS RELEASES
6/14/2024

LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
PRESS RELEASES
6/6/2024

Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
PRESS RELEASES
6/3/2024

LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”
PRESS RELEASES
5/8/2024

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
PRESS RELEASES
3/21/2024

LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level